Cargando…

Non vitamin K anticoagulation drugs will win the race

Detalles Bibliográficos
Autores principales:	Van Gelder, I. C., De With, R. R., Rienstra, M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2016
Materias:	Editorial Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5039137/ https://www.ncbi.nlm.nih.gov/pubmed/27601004 http://dx.doi.org/10.1007/s12471-016-0895-6

Ejemplares similares

Slow but steady wins the drug race
por: Wells, William A.
Publicado: (2004)

Experience with non-vitamin K antagonists in the Netherlands: stories from both sides of the desk
por: de Vries, T. A. C., et al.
Publicado: (2019)

Let’s talk about race: changing the conversations around race in academia
por: Miller-Kleinhenz, Jasmine M., et al.
Publicado: (2021)

Editorial comment on Vitamin K and vascular calcification in chronic kidney disease: An update of current evidence – The role of Vitamin K in managing chronic kidney disease–mineral bone disorder
por: Hou, Yi-Chou, et al.
Publicado: (2022)

Geographic Variations in the Quality of Oral Anticoagulation With Vitamin K Antagonists in the Era of New Anticoagulants
por: Fauchier, Laurent, et al.
Publicado: (2013)

Consideration of NOACs (novel or non-vitamin K-dependent oral anticoagulants) in dental procedure
por: Song, Jiyoung
Publicado: (2021)

Anticoagulation for Atrial Fibrillation in Cirrhosis of the Liver: Are Low‐Dose Non‐Vitamin K Oral Anticoagulants a Reasonable Alternative to Warfarin?
por: Gallagher, Celine, et al.
Publicado: (2019)

Trouble at the races
por: Jobling, Mark A
Publicado: (2014)

Drug–drug interaction between levetiracetam and non-vitamin K antagonist anticoagulants
por: Mathy, François-Xavier, et al.
Publicado: (2019)

Anticoagulation in patients with mechanical heart valves: follow the guidelines!
por: Verheugt, Freek W.A.
Publicado: (2015)

Novel oral anticoagulants: the translation of ‘de Leidraad’ into daily clinical practice
por: Jaspers Focks, J., et al.
Publicado: (2014)

Anticoagulation in COVID-19
por: Bradbury, Charlotte A, et al.
Publicado: (2022)

The Odor of the White Race
Publicado: (1903)

Sharpening the global focus on ethnicity and race in the time of COVID-19
por: Bhala, Neeraj, et al.
Publicado: (2020)

Trends in antithrombotic drug use and adherence to non-vitamin K oral anticoagulants in the Netherlands
por: Hanemaaijer, Susan, et al.
Publicado: (2015)

Off‐target effects of oral anticoagulants – vascular effects of vitamin K antagonist and non‐vitamin K antagonist oral anticoagulant dabigatran etexilate
por: van Gorp, Rick H., et al.
Publicado: (2021)

Response to editorial comment ‘Direct oral anticoagulant failure in TIA/stroke: neurologic and pharmacokinetic considerations’
por: Huynh, Ronald, et al.
Publicado: (2020)

Direct Effects of Activation and Inhibition of the Coagulation System on the Atrial Fibrillation Substrate: Is Anticoagulation Antiarrhythmic?
por: Nattel, Stanley
Publicado: (2016)

Direct oral anticoagulant failure in stroke/transient ischaemic attack: neurologic and pharmacokinetic considerations
por: Rose, David Z, et al.
Publicado: (2020)

Reduction of radiation dose using 80 kV tube voltage: a feasible strategy?
por: van der Wall, E. E., et al.
Publicado: (2011)

Atrial fibrillation and heart failure temporality: does it matter?
por: Van Deutekom, Colinda, et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Oral systemic therapy: Not all “win-win”
por: Bhattacharyya, G. S.
Publicado: (2010)

100 kV versus 120 kV: effective reduction in radiation dose?
por: van der Wall, E. E., et al.
Publicado: (2010)

Pulling at the heart: COVID-19, race/ethnicity and ongoing disparities
por: Chin-Hong, Peter, et al.
Publicado: (2020)

Anticoagulation in COVID-19: reaction to the ACTION trial
por: Berger, Jeffrey S, et al.
Publicado: (2021)

Medications that interact with direct-acting oral anticoagulant exposure
por: de Vries, T. A. C., et al.
Publicado: (2021)

How to win: the argument, the pitch, the job, the race
por: Yeung, Rob
Publicado: (2014)

Behind the mask: demedicalising race and mental health in professional football
por: Bennett, Michael
Publicado: (2021)

Inappropriate non-vitamin K antagonist oral anticoagulants prescriptions: be cautious with dose reductions
por: Jacobs, M. S., et al.
Publicado: (2019)

Evidence Gaps in the Era of Non–Vitamin K Oral Anticoagulants
por: Aronis, Konstantinos N., et al.
Publicado: (2018)

Minneapolis Wins
Publicado: (1902)

Wean to Win
por: Havaldar, Amarja Ashok, et al.
Publicado: (2023)

COVID-19 vaccine race: watch your step for cancer patients
por: Fanciullino, Raphaelle, et al.
Publicado: (2020)

Slow and steady wins the race: an examination of bacterial persistence
por: Renbarger, Tara L., et al.
Publicado: (2017)

Vitamin D and heart: A not so sunny pathway
por: Marra, Alessio
Publicado: (2015)

An Update on the Reversal of Non-Vitamin K Antagonist Oral Anticoagulants
por: Mujer, Mark Terence P., et al.
Publicado: (2020)

Warfarin or non-Vitamin K antagonist oral anticoagulants: Navigating the choice of oral anticoagulant drugs in the COVID-19 pandemic era
por: Heng, Cai, et al.
Publicado: (2020)

Voltage-dependent K(+) channels as oncotargets in malignant gliomas
por: Lefranc, Florence, et al.
Publicado: (2012)

Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)
por: Monelli, Mauro, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jpnhj92d0gdrol6bilvb5ilqp1